Auris Initiates Second Phase III For Pipeline-Leading Hearing Loss Drug
Executive Summary
Auris Medical Holding AG has moved its hearing loss therapeutic, AM-111, into a second Phase III study, making it the most advanced drug in the pipeline for the treatment of sudden deafness, according to Biomedtracker.
You may also be interested in...
Auris Sees A Window To Treat Profound Hearing Loss Despite Phase III Failure
The HEALOS trial testing AM-111 in sudden deafness did not meet the primary efficacy endpoint, but a subpopulation of patients with the worst hearing loss did show a statistically significant benefit.
Auris' Outlook Bleak In Tinnitus After Failure Of Initial Phase III Trial
The Swiss biotech still holds out hope that its NMDA antagonist Keyzilen will hit its primary endpoint in a European Phase III study in acute tinnitus, but a largely US-based first Phase III trial missed both co-primary endpoints.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.